Pancreatic cancer (PDAC) is a highly lethal malignancy, requiring efficient detection when the primary tumor is still resectable. We had previously developed the MxPancreasScore comprising nine analytes and serum CA19-9, achieving an accuracy of 90.6%. The necessity for five different analytic platforms and multiple analytic runs however hindered clinical applicability. Therefore, we aimed to develop a simpler single-analytical run, single-platform diagnostic signature.